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E-mail address: herczeghp@gmail.com (P. HerczegNew sugar derivatives of ristocetin were prepared by copper-catalyzed 1,3-dipolar cycloaddition reaction
using azido-ristocetin aglycon and various propargyl glycosides. Some of them were found to be active
against Gram-positive bacteria and showed favorable antiviral activity against the H1N1 subtype of influ-
enza A virus.
 2010 Elsevier Ltd. All rights reserved.Ristocetin A (1) is a glycopeptide-type antibiotic produced by
Nocardia lurida.1 The ristocetin molecule carries 6 sugar molecules
(2 D-mannose, D-glucose, D-arabinose, L-rhamnose and L-ristos-
amine) linked to the aglycon. In spite of its good antibacterial activ-
ity against Gram-positive strains including MRSA,2 this antibiotic
has not been used in therapy due to its ability to cause aggregation
of blood platelets.3 Williams et al. reported4 that cleavage of L-
rhamnose from ristocetin A removes this aggregating property. In
a systematic study with aglyco-ristocetin5 (2) (Scheme 1) deriva-
tives we found that deglycosylation of 1 retains the antibacterial
activity, however 2 is not suitable for platelet aggregation tests
due to its very low solubility in water. To improve solubility, we
prepared derivatives of 2 containing b-D-glucopyranosyl and b-D-
maltosyl substituents attached through an N-glycosylthiourea
moiety.6 These derivatives possessed good antibacterial activity
and did not induce platelet aggregation. These promising results
prompted us to perform a systematic study on the influence of
various sugar substituents on the biological activity of derivatives
of 2. In this work we here report on the synthesis and biological
activity of several new sugar derivatives of 2. For conjugation of
1 we have chosen D-glucose, D-mannose and L-rhamnose, sincell rights reserved.
5; fax: +36 52 512 914.
h).the ristocetin molecule also contains these saccharides. Another
glycopeptide antibiotic, teicoplanin has N-acetyl-D-glucosamine
substituent, consequently this sugar was also chosen for the
derivatisation of 1. Following our diazo-transfer-click reaction se-
quence7 3 was chosen as the starting compound. Copper-catalyzed
1,3-dipolar cycloaddition reaction (‘click reaction’)8 of the latter
with per-O-acetylated propargyl glycosides9 resulted in the carbo-
hydrate-substituted aglycons 4a–8a. Zemplén deacetylation10 of
the sugar acetate moieties led to the glycosyl–oxymethyl–triazolyl
derivatives of the ristocetin aglycon carrying saccharides with a-D-
glucopyranosyl (4b), a-D-mannopyranosyl (5b), a-D-maltopyrano-
syl (6b), a-D-N-acetylglucosaminyl (7b) and a-L-rhamnopyranosyl
(8b) configuration (Scheme 2).
Evaluation of the biological properties of these derivatives
(including the per-O-acetates) against Gram-positive bacteria
demonstrated that introduction of the sugar moieties at the N-ter-
minus into the ristocetin A aglycon molecule had a beneficial effect
on the antibacterial activity. From an analysis of the data summa-
rized in Table 1, it can be seen that the most of the new derivatives
displayed higher activity than 1. The sugar derivatives 4–7 had
good to excellent bacteriostatic activity against the test organisms,
including glycopeptide-resistant enterococci. Interestingly, in this
small group of compounds, the configuration of the sugar part
(D-sugars) exhibited only a slight influence on the MIC values.
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Scheme 1. Synthesis of the azido-ristocetin aglycon 3. Reagents and conditions: (a) HF, anisole, 18 C, 2 h, 61%; (b) TfN3, pyridine, CuSO4, Et3N, room temperature,
overnight, 58%.
2714 G. Pintér et al. / Bioorg. Med. Chem. Lett. 20 (2010) 2713–2717Derivatives 8a and 8b containing rhamnosyl glycosides of the L-su-
gar series possessed much lower activity indicating the role of the
stereochemistry in the antibacterial activity. It has to be noted that
there is only a slight difference between the MIC values ofcompounds having acetylated (a series) or free sugars (b series),
which can be explained by a possible deacetylation in the cul-
ture media by aspecific esterases. The anti-influenza virus activ-
ity of the prepared substances was also evaluated, since we
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Scheme 2. Synthesis of the per-O-acetylated and free sugar derivatives of the ristocetin aglycon. Reagents and conditions: (a) per-O-acetylated propargyl glycoside, CuI, Et3N,
dry DMF, room temperature, overnight, 38–53%; (b) NaOMe, MeOH, room temperature, overnight, 87–96%.
G. Pintér et al. / Bioorg. Med. Chem. Lett. 20 (2010) 2713–2717 2715recently discovered good to excellent activities of some deriva-
tives of 1.11 The cell-culture based assays to determine the
inhibitory effect on influenza virus replication against, have been
published elsewhere.11 Briefly, the antiviral activity was ex-
pressed as the 50% effective concentration (EC50), or compound
concentration producing 50% inhibition of influenza virus repli-
cation (as determined by microscopic or spectrophotometric
assays). These experiments also allowed to estimate the cytotox-
icity of the test compounds. As shown in Table 2, compounds
4a,b–7a,b exhibited antiviral activity against influenza virus,with the highest activity being noted for the A/H1N1 subtype
(antiviral EC50 values in the range of 6–16 lM). These four com-
pounds produced minimal, if any, cytotoxicity at 70–100 lM. We
have also studied the influence of the presence of sugar moieties
on blood platelet aggregation properties. In about 0.1 mg/mL
concentration the D-glucose and D-maltose analogs 4b and 6b
inhibited the ristocetin induced platelet aggregation. The D-man-
nose and D-glucosamine derivatives 5b and 7b had no influence,
but the L-rhamnose derivative 8b increased the intensity of
aggregation.
Table 1
Antibacterial activity of the new sugar derivatives of the ristocetin aglycon
Test microorganism MIC/MBC (lg/mL)
Ristocetin 3 4a 4b 5a 5b 6a 6b 7a 7b 8a 8b
ATCC 6633
B. subtilis
2/4 1/4 8/16 2/8 4/8 4/4 8/8 4/4 2/8 4/8 32/32 16/16
ATCC 33591 MSSA 16/64 1/2 4/8 2/128 2/4 4/16 1/4 2/256 1/64 4/4 16/32 8/16
ATCC 29213 MRSA 16/64 2/2 4/8 2/256 2/4 2/216 1/4 4/256 0.5/256 2/2 16/32 8/8
ATCC 35984
S. epidermidis
Biofilm-positive
32/64 8/16 2/4 4/4 4/8 4/8 4/8 8/8 2/2 4/4 16/16 16/16
S. epidermidis 4/8 16/16 2/4 4/16 4/4 4/8 4/4 4/8 1/2 2/4 16/32 16/16
ATCC 29212
E. faecalis
Vanco: S
Teico: S
4/256 8/16 8/256 4/256 4/128 8/256 4/256 4/256 4/256 8/256 32/256 32/256
ATCC 51299
E. faecalis
Vanco: R
Teico: S
VanB +
128/256 64/128 16/256 8/256 8/256 16/256 8/256 32/256 4/256 16/256 128/256 64/128
15376a
E. faecalis
Vanco: R
Teico: R
VanA +
128/256 >256 8/256 4/256 2/128 16/64 2/256 8/256 2/256 8/256 16/256 16/256
MIC: Minimum Inhibitory Concentration, MBC: Minimum Bactericidal Concentration, ATCC: American Typed Culture Collection, MSSA: Methicillin Sensitive Staphylococcus
aureus, MRSA: Methicillin Resistant Staphylococcus aureus, Vanco/Teico R: Vancomycin/Teicoplanin Resistant, Vanco/Teico S: Vancomycin/Teicoplanin Sensitive, vanA +: vanA
gene positive, vanB +: vanB gene positive.
a Ref. 12.
Table 2
Anti-influenza virus activity of the new sugar derivatives of the ristocetin aglycon
Compound Concentration unit Cytotoxicity Antiviral EC50c
CC50a Minimum cytotoxic concentrationb Influenza A/H1N1 Influenza A/H3N2 Influenza B
CPE MTS CPE MTS CPE MTS
3 lM P53 100 9.5 8.8 P20 P9 >100 >100
4a lM P87 P100 9.5 8.2 >100 >100 >100 >100
4b lM >100 P100 14 16 P45 P30 32 33
5a lM >100 20 4.0 5.0 >100 >100 >100 >100
5b lM >100 P100 10 22 P45 P46 P45 P50
6a lM 60 20 >100 >100 >100 >100 >100 >100
6b lM >100 P100 16 20 >100 >100 52 61
7a lM P70 100 8.0 5.8 >100 >100 >100 >100
7b lM >100 P100 9.0 8.7 P45 P72 32 40
8a lM >100 >100 >100 >100 >100 >100 >100 >100
8b lM >100 >100 >100 >100 >100 >100 >100 >100
Oseltamivir carboxylate lM >100 >100 12 11 32 38 23 27
Ribavirin lM >100 >100 9.0 11 9.0 8.7 4.0 4.7
Amantadine lM >500 >500 20 19 7.0 9.2 >500 >500
Rimantadine lM >500 >500 224 283 4.0 5.6 >500 >500
CPE: cytopathic effect.
MTS: methyltetrazolium salt.
Data shown are the mean of two independent tests.
a 50% cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.
b Minimum compound concentration that causes a microscopically detectable alteration of normal cell morphology.
c 50% effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by visual scoring of the CPE, or by measuring the
cell viability with the colorimetric formazan-based MTS assay.
2716 G. Pintér et al. / Bioorg. Med. Chem. Lett. 20 (2010) 2713–2717In summary, it is demonstrated that resubstitution of aglyco-
ristocetin with saccharides by the ‘click reaction’ dramatically im-
proves the antibacterial activity against glycopeptide-resistant
enterococci and leads to anti-influenza virus derivatives. It turned
out that the platelet aggregation activity can be effectively
modified by introduction of various saccharides into the ristocetin
aglycon molecule.
In order to improve and extend the antibacterial and antiviral
activity, derivatisation of aglyco-ristocetin with further mono-and oligosaccharides with D and L configuration, as well as deoxy
and deoxyamino sugars and other side chains with hydrophilic
character is under way in our laboratory.
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